NCT06733610
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With AIHA Who Have Failed ≥3 Lines of Therapy.
StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Feb 5, 2026 to Jan 12, 2027 Show 7 more changesShow less
- Eligibility criteria expanded, about 24 words
- Enrollment closed, study ongoing
- Final enrollment: 5 participants (planned 15)
- Study completion pushed from Dec 5, 2026 to Dec 31, 2027
- Interventions: universal allogeneic anti-CD19/BCMA CAR T-cells (Biological) to universal allogeneic anti-CD19/BCMA CAR T-cells (Biological)
- Site details revised
- Collaborators: details revised at 1 of 1 entry
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
The number and severity of dose-limiting toxicity (DLT) events
Timeframe: Within 28 Days After UCAR T-cell Infusion
The total number, incidence, and severity of AEs
Timeframe: Up to 12 Months After UCAR T-cell Infusion
Clinical response of AIHA who have failed ≥ 3 lines of therapy
Timeframe: Up to 24 Weeks After UCAR T-cell Infusion
Arms and interventions
UCAR T-cell groupExperimental
Universal allogeneic anti-CD19/BCMA CAR T-cells.
Biologicals: universal allogeneic anti-CD19/BCMA CAR T-cells
Sites
1 site in 1 country
- Regenerative Medicine Center and Red Blood Cell Disorders CenterTianjin, Tianjin Municipality, China